Orion Oyj engages in the development of pharmaceutical and diagnostic test. It develops, manufactures, and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. Its pharmaceutical research and development focuses on central nervous system drugs, oncology and critical care drugs, and Easyhaler pulmonary drugs. The company operates through the following segments: Pharmaceuticals and Diagnostics. The Pharmaceuticals segment researches, develops, manufactures and markets pharmaceuticals and active pharmaceutical ingredients, which comprises Proprietary Products, which provides patented prescription products; Specialty Products, which offers off-patent prescription drugs and self-care products; Animal Health, which manufactures veterinary products for pets and production animals; Fermion, which is engaged in active pharmaceutical ingredients. The Diagnostics segment develops, manufactures, and markets diagnostic tests, such as in vitro diagnostic tests and testing systems suitable for point-of-care testing. Orion was founded by Onni Turpeinen, Eemil Tuurala and Wikki Valkama on September 21, 1917 and is headquartered in Espoo, Finland.